Second primary cancers related to smoking and treatment of small-cell lung cancer

Margaret A. Tucker, Nevin Murray, Edward G. Shaw, David S. Ettinger, Mack Mabry, Martin H. Huber, Ronald Feld, Frances A. Shepherd, David H. Johnson, Stefan C. Grant, Joseph Aisner, Bruce E. Johnson

Research output: Contribution to journalArticle

166 Citations (Scopus)

Abstract

Background: An increased risk of second primary cancers has been reported in patients who survive small-cell carcinoma of the lung. The treatment's contribution to the development of second cancers is difficult to assess, in part because the number of long-term survivors seen at any one institution is small. We designed a multi-institution study to investigate the risk among survivors of developing second primary cancers other than small-cell lung carcinoma. Methods: Demographic, smoking, and treatment information were obtained from the medical records of 611 patients who had been cancer free for more than 2 years after therapy for histologically proven small-cell lung cancer, and personyears of follow-up were cumulated. Population-based rates of cancer incidence and mortality were used to estimate the expected number of cancers or deaths. The actuarial risk of second cancers was estimated by the Kaplan-Meier method. Results: Relative to the general population, the risk of all second cancers among these patients (mostly non-small-cell cancers of the lung) was increased 3.5-fold. Second lung cancer risk was increased 13-fold among those who received chest irradiation in comparison to a sevenfold increase among nonirradiated patients. It was higher in those who continued smoking, with evidence of an interaction between chest irradiation and continued smoking (relative risk = 21). Patients treated with various forms of combination chemotherapy had comparable increases in risk (9.4- to 13-fold, overall), except for a 19- fold risk increase among those treated with alkylating agents who continued smoking. Implications: Because of their substantially increased risk, survivors should stop smoking and may consider entering trials of secondary chemoprevention.

Original languageEnglish (US)
Pages (from-to)1782-1788
Number of pages7
JournalJournal of the National Cancer Institute
Volume89
Issue number23
StatePublished - Dec 3 1997

Fingerprint

Second Primary Neoplasms
Small Cell Lung Carcinoma
Smoking
Survivors
Therapeutics
Thorax
Neoplasms
Alkylating Agents
Chemoprevention
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Population
Medical Records
Lung Neoplasms
Demography
Mortality
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tucker, M. A., Murray, N., Shaw, E. G., Ettinger, D. S., Mabry, M., Huber, M. H., ... Johnson, B. E. (1997). Second primary cancers related to smoking and treatment of small-cell lung cancer. Journal of the National Cancer Institute, 89(23), 1782-1788.

Second primary cancers related to smoking and treatment of small-cell lung cancer. / Tucker, Margaret A.; Murray, Nevin; Shaw, Edward G.; Ettinger, David S.; Mabry, Mack; Huber, Martin H.; Feld, Ronald; Shepherd, Frances A.; Johnson, David H.; Grant, Stefan C.; Aisner, Joseph; Johnson, Bruce E.

In: Journal of the National Cancer Institute, Vol. 89, No. 23, 03.12.1997, p. 1782-1788.

Research output: Contribution to journalArticle

Tucker, MA, Murray, N, Shaw, EG, Ettinger, DS, Mabry, M, Huber, MH, Feld, R, Shepherd, FA, Johnson, DH, Grant, SC, Aisner, J & Johnson, BE 1997, 'Second primary cancers related to smoking and treatment of small-cell lung cancer', Journal of the National Cancer Institute, vol. 89, no. 23, pp. 1782-1788.
Tucker MA, Murray N, Shaw EG, Ettinger DS, Mabry M, Huber MH et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Journal of the National Cancer Institute. 1997 Dec 3;89(23):1782-1788.
Tucker, Margaret A. ; Murray, Nevin ; Shaw, Edward G. ; Ettinger, David S. ; Mabry, Mack ; Huber, Martin H. ; Feld, Ronald ; Shepherd, Frances A. ; Johnson, David H. ; Grant, Stefan C. ; Aisner, Joseph ; Johnson, Bruce E. / Second primary cancers related to smoking and treatment of small-cell lung cancer. In: Journal of the National Cancer Institute. 1997 ; Vol. 89, No. 23. pp. 1782-1788.
@article{a561840c25b04046a04413094def39f8,
title = "Second primary cancers related to smoking and treatment of small-cell lung cancer",
abstract = "Background: An increased risk of second primary cancers has been reported in patients who survive small-cell carcinoma of the lung. The treatment's contribution to the development of second cancers is difficult to assess, in part because the number of long-term survivors seen at any one institution is small. We designed a multi-institution study to investigate the risk among survivors of developing second primary cancers other than small-cell lung carcinoma. Methods: Demographic, smoking, and treatment information were obtained from the medical records of 611 patients who had been cancer free for more than 2 years after therapy for histologically proven small-cell lung cancer, and personyears of follow-up were cumulated. Population-based rates of cancer incidence and mortality were used to estimate the expected number of cancers or deaths. The actuarial risk of second cancers was estimated by the Kaplan-Meier method. Results: Relative to the general population, the risk of all second cancers among these patients (mostly non-small-cell cancers of the lung) was increased 3.5-fold. Second lung cancer risk was increased 13-fold among those who received chest irradiation in comparison to a sevenfold increase among nonirradiated patients. It was higher in those who continued smoking, with evidence of an interaction between chest irradiation and continued smoking (relative risk = 21). Patients treated with various forms of combination chemotherapy had comparable increases in risk (9.4- to 13-fold, overall), except for a 19- fold risk increase among those treated with alkylating agents who continued smoking. Implications: Because of their substantially increased risk, survivors should stop smoking and may consider entering trials of secondary chemoprevention.",
author = "Tucker, {Margaret A.} and Nevin Murray and Shaw, {Edward G.} and Ettinger, {David S.} and Mack Mabry and Huber, {Martin H.} and Ronald Feld and Shepherd, {Frances A.} and Johnson, {David H.} and Grant, {Stefan C.} and Joseph Aisner and Johnson, {Bruce E.}",
year = "1997",
month = "12",
day = "3",
language = "English (US)",
volume = "89",
pages = "1782--1788",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "23",

}

TY - JOUR

T1 - Second primary cancers related to smoking and treatment of small-cell lung cancer

AU - Tucker, Margaret A.

AU - Murray, Nevin

AU - Shaw, Edward G.

AU - Ettinger, David S.

AU - Mabry, Mack

AU - Huber, Martin H.

AU - Feld, Ronald

AU - Shepherd, Frances A.

AU - Johnson, David H.

AU - Grant, Stefan C.

AU - Aisner, Joseph

AU - Johnson, Bruce E.

PY - 1997/12/3

Y1 - 1997/12/3

N2 - Background: An increased risk of second primary cancers has been reported in patients who survive small-cell carcinoma of the lung. The treatment's contribution to the development of second cancers is difficult to assess, in part because the number of long-term survivors seen at any one institution is small. We designed a multi-institution study to investigate the risk among survivors of developing second primary cancers other than small-cell lung carcinoma. Methods: Demographic, smoking, and treatment information were obtained from the medical records of 611 patients who had been cancer free for more than 2 years after therapy for histologically proven small-cell lung cancer, and personyears of follow-up were cumulated. Population-based rates of cancer incidence and mortality were used to estimate the expected number of cancers or deaths. The actuarial risk of second cancers was estimated by the Kaplan-Meier method. Results: Relative to the general population, the risk of all second cancers among these patients (mostly non-small-cell cancers of the lung) was increased 3.5-fold. Second lung cancer risk was increased 13-fold among those who received chest irradiation in comparison to a sevenfold increase among nonirradiated patients. It was higher in those who continued smoking, with evidence of an interaction between chest irradiation and continued smoking (relative risk = 21). Patients treated with various forms of combination chemotherapy had comparable increases in risk (9.4- to 13-fold, overall), except for a 19- fold risk increase among those treated with alkylating agents who continued smoking. Implications: Because of their substantially increased risk, survivors should stop smoking and may consider entering trials of secondary chemoprevention.

AB - Background: An increased risk of second primary cancers has been reported in patients who survive small-cell carcinoma of the lung. The treatment's contribution to the development of second cancers is difficult to assess, in part because the number of long-term survivors seen at any one institution is small. We designed a multi-institution study to investigate the risk among survivors of developing second primary cancers other than small-cell lung carcinoma. Methods: Demographic, smoking, and treatment information were obtained from the medical records of 611 patients who had been cancer free for more than 2 years after therapy for histologically proven small-cell lung cancer, and personyears of follow-up were cumulated. Population-based rates of cancer incidence and mortality were used to estimate the expected number of cancers or deaths. The actuarial risk of second cancers was estimated by the Kaplan-Meier method. Results: Relative to the general population, the risk of all second cancers among these patients (mostly non-small-cell cancers of the lung) was increased 3.5-fold. Second lung cancer risk was increased 13-fold among those who received chest irradiation in comparison to a sevenfold increase among nonirradiated patients. It was higher in those who continued smoking, with evidence of an interaction between chest irradiation and continued smoking (relative risk = 21). Patients treated with various forms of combination chemotherapy had comparable increases in risk (9.4- to 13-fold, overall), except for a 19- fold risk increase among those treated with alkylating agents who continued smoking. Implications: Because of their substantially increased risk, survivors should stop smoking and may consider entering trials of secondary chemoprevention.

UR - http://www.scopus.com/inward/record.url?scp=0030724601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030724601&partnerID=8YFLogxK

M3 - Article

VL - 89

SP - 1782

EP - 1788

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 23

ER -